Hualien Pharmaceutical-B (02552.HK) filed its latest Securities Monthly Change Report on February 29, 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED IN FEBRUARY, AT 2,000,000,000 SHARES OF ORDINARY SHARES WITH A FACE VALUE OF $0.001 PER SHARE AND A TOTAL STATUTORY/REGISTERED SHARE CAPITAL OF $2,000,000. In addition, under the Company's stock option plan, the number of share options available at the end of February was 53,797,568 shares, and therefore no new shares were issued during the month. COMPANY SECRETARY YUAN WING-XIN SUBMITTED THE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 5 MARCH 2024, CONFIRMING THAT ALL RELEVANT SECURITIES WERE APPROVED BY THE BOARD OF DIRECTORS AND COMPLIED WITH THE LISTING RULES OF THE HONG KONG STOCK EXCHANGE LIMITED.

Hualien Pharmaceutical-B (02552.HK) filed its latest Securities Monthly Change Report on February 29, 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED IN FEBRUARY, AT 2,000,000,000 SHARES OF ORDINARY SHARES WITH A FACE VALUE OF $0.001 PER SHARE AND A TOTAL STATUTORY/REGISTERED SHARE CAPITAL OF $2,000,000. In addition, under the Company's stock option plan, the number of share options available at the end of February was 53,797,568 shares, and therefore no new shares were issued during the month. COMPANY SECRETARY YUAN WING-XIN SUBMITTED THE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 5 MARCH 2024, CONFIRMING THAT ALL RELEVANT SECURITIES WERE APPROVED BY THE BOARD OF DIRECTORS AND COMPLIED WITH THE LISTING RULES OF THE HONG KONG STOCK EXCHANGE LIMITED.